Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
2019 · Nature Communications · 383 citations
https://doi.org/10.1038/s41467-019-09068-2
S
Sarah Croessmann
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
102
Papers
2.5K
Citations
22
h-index
30
i10-index
Sarah Croessmann is an academic researcher. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 22, co-authored 87 publications.
ORCID: 0000-0002-7366-0400Papers by this author
worksMutation of a single allele of the cancer susceptibility gene <i>BRCA1</i> leads to genomic instability in human breast epithelial cells
2011 · Proceedings of the National Academy of Sciences · 163 citations
https://doi.org/10.1073/pnas.1110969108
Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
2018 · Clinical Cancer Research · 109 citations
https://doi.org/10.1158/1078-0432.ccr-18-1544
<i>HER2</i>missense mutations have distinct effects on oncogenic signaling and migration
2015 · Proceedings of the National Academy of Sciences · 82 citations
https://doi.org/10.1073/pnas.1516853112
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
2018 · Clinical Cancer Research · 45 citations
https://doi.org/10.1158/1078-0432.ccr-18-1131
Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones
2021 · Journal of Clinical Investigation · 16 citations
https://doi.org/10.1172/jci143557
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat